Bisphosphonates vs placebo
Number of participants who needed orthopaedic surgery (not measured) · Paget's disease of bone
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsGRADE not reported
Findings
What do systematic reviews say?
94 questions · 94 findings · 8 reviews · Headline outcomes only
No studies found 8 · 8.5%GRADE not reported 13 · 13.8%Very low 22 · 23.4%Low 17 · 18.1%Moderate 23 · 24.5%High 11 · 11.7%
Bisphosphonates vs placebo
Number of participants with change in quality of life measures (not measured) · Paget's disease of bone
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsGRADE not reported
Bisphosphonates vs placebo
Number of participants with change in hearing thresholds (not measured) · Paget's disease of bone
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsGRADE not reported
Bisphosphonates vs placebo
Withdrawals due to adverse events · Paget's disease of bone
Bisphosphonates showed no clear difference in number of participants who withdrew due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 1.01 [0.41, 2.52]6 studies · 517 participantsLow
Bisphosphonates vs placebo/no treatment
Proportion of participants with pain response · men with advanced prostate cancer
Bisphosphonates showed no clear difference in proportion of participants with pain response compared with placebo/no treatment (low certainty).
1 finding from 1 review
- RR 1.15 [0.93, 1.43]3 studies · 876 participantsLow
Bisphosphonates vs placebo/no treatment
Skeletal‐related event (SRE) · men with advanced prostate cancer
Bisphosphonates probably leads to lower skeletal‐related events: any, composite outcome compared with placebo/no treatment (moderate certainty).
1 finding from 1 review
- RR 0.87 [0.81, 0.94]9 studies · 3153 participantsModerate
Bisphosphonates vs placebo/no treatment
All‐cause mortality · men with advanced prostate cancer
Bisphosphonates showed no clear difference in mortality compared with placebo/no treatment (moderate certainty).
1 finding from 1 review
- RR 0.97 [0.91, 1.04]9 studies · 2450 participantsModerate
Bisphosphonates vs placebo/no treatment
Quality of life · men with advanced prostate cancer
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Bisphosphonates vs placebo/no treatment
Adverse events: nausea · men with advanced prostate cancer
Bisphosphonates showed no clear difference in adverse events: nausea compared with placebo/no treatment (moderate certainty).
1 finding from 1 review
- RR 1.19 [1, 1.41]9 studies · 3008 participantsModerate
Bisphosphonates vs placebo/no treatment
Adverse events: renal · men with advanced prostate cancer
Bisphosphonates probably leads to higher adverse events: renal compared with placebo/no treatment (moderate certainty).
1 finding from 1 review
- RR 1.65 [1.11, 2.46]7 studies · 1794 participantsModerate
Bisphosphonates vs placebo/no treatment
Adverse events: osteonecrosis of the jaw · men with advanced prostate cancer
It is very uncertain whether bisphosphonates changes adverse events: osteonecrosis of the jaw compared with placebo/no treatment (very low certainty).
1 finding from 1 review
- RR 1.92 [0.75, 4.9]5 studies · 1626 participantsVery low
Bisphosphonates vs placebo/no treatment
Disease progression · men with advanced prostate cancer
Bisphosphonates probably leads to lower proportion of participants with disease progression compared with placebo/no treatment (moderate certainty).
1 finding from 1 review
- RR 0.95 [0.9, 0.99]7 studies · 2115 participantsModerate
Bisphosphonates vs control
Incident vertebral fractures Radiographic · adults with GIOP
Bisphosphonates leads to lower incident vertebral fractures Radiographic compared with control (high certainty).
1 finding from 1 review
- RR 0.57 [0.35, 0.91]12 studies · 1343 participantsHigh
Bisphosphonates vs control
Incident nonvertebral fractures Radiographic · adults with GIOP
Bisphosphonates showed no clear difference in incident nonvertebral fractures Radiographic compared with control (low certainty).
1 finding from 1 review
- RR 0.79 [0.47, 1.33]9 studies · 1245 participantsLow
Bisphosphonates vs control
Lumbar spine bone mineral density (BMD) · adults with GIOP
1 finding from 1 review
- no estimate extracted23 studies · 2042 participantsModerate
Bisphosphonates vs control
Femoral neck bone mineral density (FN-BMD) · adults with GIOP
1 finding from 1 review
- no estimate extracted18 studies · 1665 participantsModerate
Bisphosphonates vs control
Serious adverse events · adults with GIOP
Bisphosphonates showed no clear difference in serious adverse events compared with control (low certainty).
1 finding from 1 review
- RR 0.91 [0.74, 1.12]15 studies · 1703 participantsLow
Bisphosphonates vs control
Withdrawals due to adverse events · adults with GIOP
Bisphosphonates showed no clear difference in withdrawals due to adverse events compared with control (low certainty).
1 finding from 1 review
- RR 1.06 [0.77, 1.47]15 studies · 1790 participantsLow
Bisphosphonates vs control
Quality of life · adults with GIOP
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsGRADE not reported
Bisphosphonates vs placebo or no intervention
All‐cause mortality · patients with primary biliary cirrhosis.
It is very uncertain whether bisphosphonates changes all‐cause mortality compared with placebo or no intervention (very low certainty).
1 finding from 1 review
- Bisphosphonates for osteoporosis in primary biliary cirrhosis 2011 · Cochrane Headline outcomes onlyRD 02 studies · 46 participantsVery low